Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.21 -0.8%	$7.24	$3.54 ▼ $8.90	$175.78M	0.8	110,492 shs	115,184 shs
EPRX Eupraxia Pharmaceuticals	$5.34 +1.3%	$5.28	$2.20 ▼ $6.20	$192.28M	1.5	13,187 shs	14,812 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	100 shs
VTYX Ventyx Biosciences	$2.40 -2.1%	$2.64	$0.78 ▼ $3.39	$169.29M	0.97	1.34 million shs	282,064 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	-2.81%	+2.68%	-4.22%	-9.80%	+41.17%
EPRX Eupraxia Pharmaceuticals	-0.19%	+1.35%	-5.56%	+34.10%	+101.15%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%
VTYX Ventyx Biosciences	-2.39%	-7.55%	-8.24%	+46.27%	+11.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DERM Journey Medical	1.7375 of 5 stars	3.3	1.0	0.0	0.0	2.7	0.8	0.6
EPRX Eupraxia Pharmaceuticals	2.2388 of 5 stars	3.6	1.0	0.0	0.0	2.6	0.0	0.6
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	2.5818 of 5 stars	3.3	3.0	0.0	0.0	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	2.50	Moderate Buy	$12.17	69.33% Upside
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	107.20% Upside
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A
VTYX Ventyx Biosciences	2.50	Moderate Buy	$7.50	219.83% Upside

Current Analyst Ratings Breakdown

Latest NBRV, EPRX, DERM, and VTYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	DERM Journey Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
8/20/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/15/2025	DERM Journey Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$56.13M	3.12	N/A	N/A	$0.79 per share	9.09
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	($0.30) per share	N/A
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$2.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$14.67M	-$0.38	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	11/11/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.85	N/A	N/A	N/A	N/A	-367.73%	-126.38%	11/6/2025 (Estimated)
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A
VTYX Ventyx Biosciences	-$135.12M	-$1.68	N/A	N/A	N/A	N/A	-48.89%	-44.87%	11/6/2025 (Estimated)

Latest NBRV, EPRX, DERM, and VTYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
8/12/2025	Q2 2025	EPRX Eupraxia Pharmaceuticals	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A
8/7/2025	Q2 2025	VTYX Ventyx Biosciences	-$0.45	-$0.38	+$0.07	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	1.11	1.27	0.95
EPRX Eupraxia Pharmaceuticals	N/A	8.72	8.72
NBRV Nabriva Therapeutics	0.12	0.85	0.52
VTYX Ventyx Biosciences	N/A	19.12	19.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
EPRX Eupraxia Pharmaceuticals	N/A
NBRV Nabriva Therapeutics	0.27%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	15.03%
EPRX Eupraxia Pharmaceuticals	N/A
NBRV Nabriva Therapeutics	1.63%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	24.38 million	20.71 million	N/A
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable
VTYX Ventyx Biosciences	30	71.31 million	60.98 million	Optionable

NBRV, EPRX, DERM, and VTYX Headlines

Recent News About These Companies

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

August 27 at 7:02 AM | globenewswire.com

H.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)

August 23, 2025 | theglobeandmail.com

Piper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)

August 23, 2025 | theglobeandmail.com

Ventyx Biosciences Reports Decreased Losses in 2025

August 15, 2025 | msn.com

3 Best Stocks to Buy Now, 8/11/2025, According to Top Analysts

August 11, 2025 | msn.com

Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to "Hold"

August 10, 2025 | marketbeat.com

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

August 9, 2025 | finance.yahoo.com

Ventyx (VTYX) Q2 Net Loss Drops 16%

August 9, 2025 | theglobeandmail.com

Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expands By 69,900.0%

August 2, 2025 | marketbeat.com

Monaco Asset Management SAM Has $1.31 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

July 30, 2025 | marketbeat.com

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

July 22, 2025 | uk.finance.yahoo.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - Nasdaq

July 11, 2025 | nasdaq.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 10, 2025 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)

June 24, 2025 | theglobeandmail.com

VTYX - Ventyx Biosciences Inc News - Morningstar

June 24, 2025 | morningstar.comM

VTYX - Ventyx Biosciences Inc Financials - Morningstar

June 24, 2025 | morningstar.comM

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m

June 17, 2025 | finance.yahoo.com

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives

June 17, 2025 | marketwatch.com

Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial

June 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV, EPRX, DERM, and VTYX Company Descriptions

Journey Medical NASDAQ:DERM

$7.21 -0.06 (-0.83%)

As of 03:52 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.34 +0.07 (+1.25%)

As of 03:49 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Ventyx Biosciences NASDAQ:VTYX

$2.40 -0.05 (-1.84%)

As of 03:51 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time